alcohol abuse disorder

(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction A compound developed by Israeli psychedelics company Clearmind Medicine (NASDAQ: CMND) would act by providing a similar feeling to...

Psychedelics biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF) has published information pertaining to the safety and efficacy of its flagship molecule, called MEAI or CMND-100, after its pre-IND meeting with the Food and Drug Administration on Wednesday. MEAI is a proprietary psychedelic...